XORTX Therapeutics Files October 2025 6-K Report
Ticker: XRTX · Form: 6-K · Filed: Oct 21, 2025 · CIK: 1729214
Sentiment: neutral
Topics: reporting, 6-K, foreign-private-issuer
TL;DR
XORTX filed its monthly 6-K, confirming 20-F annual reports. Nothing major, just housekeeping.
AI Summary
XORTX Therapeutics Inc. filed a Form 6-K on October 21, 2025, reporting for the month of October 2025. The filing was signed by CEO Allen Davidoff on October 20, 2025, indicating the company is a foreign private issuer and files annual reports under Form 20-F.
Why It Matters
This filing provides routine updates for XORTX Therapeutics Inc. as a foreign private issuer, informing investors about their ongoing reporting status.
Risk Assessment
Risk Level: low — This is a routine filing (6-K) that does not contain new financial information or material events.
Key Players & Entities
- XORTX Therapeutics Inc. (company) — Registrant
- Allen Davidoff (person) — Chief Executive Officer
- October 20, 2025 (date) — Date of signature
- October 2025 (date) — Reporting period
- 20251021 (date) — Filing date
FAQ
What is the purpose of a Form 6-K filing?
A Form 6-K is a report of foreign private issuers pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934, used to provide information that the company may be required to disclose or make public in its home country.
Which annual report form does XORTX Therapeutics Inc. file?
XORTX Therapeutics Inc. files its annual reports under cover of Form 20-F.
Who signed the Form 6-K on behalf of XORTX Therapeutics Inc.?
The Form 6-K was signed by Allen Davidoff, Chief Executive Officer.
What is the filing date of this Form 6-K?
The filing date of this Form 6-K is October 21, 2025.
What is the reporting period for this Form 6-K?
This Form 6-K reports for the month of October 2025.
Filing Stats: 139 words · 1 min read · ~1 pages · Grade level 10.7 · Accepted 2025-10-20 20:44:31
Filing Documents
- f6k_102125.htm (6-K) — 4KB
- exh_991.htm (EX-99.1) — 8KB
- 0001171843-25-006532.txt ( ) — 13KB
From the Filing
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2025 Commission File Number: 001-40858 XORTX Therapeutics Inc. 3710 – 33rd Street NW, Calgary, Alberta, T2L 2M1 Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. Form 20-F [ X ] Form 40-F [ ] SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. XORTX Therapeutics Inc. (Registrant) Date: October 20, 2025 By: /s/ Allen Davidoff Name: Allen Davidoff Title: Chief Executive Officer EXHIBIT INDEX 99.1 News release dated October 20, 2025